SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
Recent Articles
- Moducore's Partnership with NVIDIA: A Leap in Offsite Tech
- Landsea Homes Corporation Acquisition Under Investigation
- Ashley Whittaker Appointed to Sports ETA Board as Partner Rep
- Conservatory Cannabis Partners with Good Time Tricycle Productions
- Willamette Valley Vineyards Announces First Quarter Losses
- Teamsters Advocate for Human Operators in Autonomous Vehicles
- Innventure, Inc. Prepares to Reveal Q1 2025 Financial Data
- Peyto Exploration Reports Strong Q1 2025 Financial Results
- Aja Health and Wellness Updates on Filing of Annual Statements
- Legal Update on Canopy Growth Corporation's Securities Case
- Investors Urged to Act on Civitas Resources Class Action
- Condor Energies Reports Positive Growth and New LNG Facility Plans
- Auburn National Bancorporation Announces Quarterly Dividend Details
- Melcor Developments Reports Positive Q1 Growth and Dividend
- Brookfield Infrastructure's $250 Million Note Offering Explained
- Optiva Inc. Delivers Strong Q1 2025 Results with Growth Plans
- Southwest Airlines Announces Latest Quarterly Dividend Update
- Baiya International Group Inc. Posts Strong Fiscal Results
- Economic Challenges Reflected in Consumer Sentiment Survey
- Elevate Your Awareness: Discover Elevance Health's Actions
- Carbon Streaming's Q1 2025 Results Highlight Strategic Moves
- SoundThinking Celebrates Law Enforcement During Police Week 2025
- TWFG Celebrates Impressive Revenue and Growth in Q1 2025
- Innovative Heart Device Developments: Anteris Reports Growth
- Capital Power Secures $1.2 Billion in Senior Notes Financing
- Keg Royalties Income Fund Shares Election Results for Trustees
- Magnetic North Acquisition Corp. Launches New Investment Offering
- Ferrovial Plans Innovative Scrip Dividend for Shareholders
- DJS Law Group Looks into Ibotta, Inc. Securities Issues
- Nutex Health Sees Record Growth in Q1 2025 Performance
- Innovative Eyewear Reports Impressive Growth for Q1 2025
- Titanium Transportation Group Achieves Notable Revenue Growth
- NanoXplore's Q3-2025 Financial Results Reveal Positive Trends
- Investigation of Ibotta, Inc. Over Potential Fraud Claims
- Investors' Call to Action: Join Treace Medical Lawsuit Today
- Liver Fibrosis Market Insights: Transforming Treatment and Growth
- Investors Seek Justice: Join Ultra Clean Holdings Lawsuit Now
- Protecting Investor Rights: enCore Energy Corp. Class Action Insights
- Investors Alert: Take Action Against Firsthand Technology Fund
- Affordable Technology Solutions with Human-I-T's Initiative
- Understanding Compass Diversified's Recent Legal Investigation
- UnitedHealth Group's Investors Can Join Important Securities Case
- NowVertical Celebrates Recognition as Top Qlik Partner in 2024
- MDWerks Unveils Exciting Developments and Growth Plans
- Discover New Townhome Floor Plans at Yarbrough Farms
- Alico's Q2 Financial Report: Focus Shifts to Diversified Land
- Liberty Gold Posts Strong Q1 2025 Financial Performance
- Cruise Planners Earns Esteemed ESGR Seven Seals Award
- First Bank's Heartwarming Donation to Youth Programs through hockey
- Innovative Inpatient Mental Health Care Program Unveiled